2. A(H1N1)pdm09 - Cell culture-derived - Northern Hemisphere 2022-2023
Influenza A(H1N1)pdm09 cell culture-derived candidate vaccine viruses or recombinant vaccine antigen(s) for development and production of vaccines for use in the 2022-2023 northern hemisphere influenza season
Overview
Human influenza virus isolation using a certified cell line (e.g. MDCK 33016 PFa, NIID-MDCKb) has been performed by WHO Collaborating Centres (CCs) of the WHO Global Influenza Surveillance and Response System (GISRS). The WHO CCs also perform antigenic and genetic analysis on the cell cultured Candidate Vaccine Viruses (ccCVVs). Unless otherwise specified, these ccCVVs have passed two-way haemagglutination inhibition (HI) or virus neutralization (VN) tests against the cell culture propagated prototype viruses matching the WHO recommendation2. No other testing (including adventitious agents) has been performed on these ccCVVs by the WHO CCs. National or regional control authorities generally approve the manufacture, composition and formulation of influenza vaccines used in each country3. Manufacturers should consult relevant national or regional control authorities regarding the suitability of using these ccCVVs for influenza vaccine production.